Forum Πρωτοβάθμιας Φροντίδας Υγείας
ΠΦΥ -Εκπαίδευση => Αποσπάσματα από τον έντυπο & ηλεκτρονικό τύπο => Μήνυμα ξεκίνησε από: Argirios Argiriou στις 1 Οκτωβρίου 2024, 17:09:54
-
Originally Published 17 March 2022
Arteriosclerosis, Thrombosis, and Vascular Biology
Volume 42, Number 5
https://doi.org/10.1161/ATVBAHA.121.317171
Highlights
•
The benefits of direct oral anticoagulants in patients with coronary artery disease without an indication for oral anticoagulation are still debated.
•
The combination of direct oral anticoagulants and antiplatelet medications can increase the bleeding risk in patients and a thorough risk and benefit assessment needs to be considered.
•
In patients with atrial fibrillation and stable coronary artery disease, newer guidelines recommend continuation of direct oral anticoagulants without the addition of an antiplatelet agent.
•
Other novel anticoagulants which have inherently lower bleeding risks while retaining ischemic benefits may soon become available.
https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.317171 (https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.317171)